graves disease epidemiology forecast

Key Highlights

• The total prevalent cases of Graves’ disease in the 7MM were ~7,166,300 in 2024. The prevalence of Graves’ disease in Japan is significantly lower than in Europe and the US.
• The US accounted for the highest number of prevalent cases of Graves’ disease, i.e., ~3,419,650 in 2024. 
• Among the gender-specific cases, females account for the largest proportion of Graves’ disease, representing approximately 80%.
• Among the EU4 and the UK, the highest number of Graves’ disease prevalent cases were found in Germany, i.e., ~743,810 in 2024, whereas Spain accounted for the lowest i.e., ~588,620 in 2024.
• Among the three Graves’ disease manifestations, Japan accounted for ~93,700 cases of Graves' ophthalmopathy, ~10,650 cases of Graves' dermopathy, and ~2,130 cases of Graves' acropachy in 2024.
• While Graves’ disease is not directly related to aging, its incidence peaks between ages 30 and 50, and certain complications are more common in the elderly.

DelveInsight’s “Graves’ Disease – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Graves’ disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Graves’ Disease Understanding

Graves’ disease is a disease affecting the thyroid and often the skin and eyes. Graves’ disease is characterized by abnormal enlargement of the thyroid (goiter) and increased secretion of thyroid hormone (hyperthyroidism). Thyroid hormones are involved with many different systems of the body, and consequently, the specific symptoms and signs of Graves’ disease can vary widely from one person to another.

Graves’ disease is further categorized into three distinct subtypes, each characterized by specific clinical features and variations in pathophysiology:

• Graves’ Dermopathy
• Graves’ Orbitopathy/Ophthalmopathy
• Graves' Acropachy

Graves’ Disease Diagnosis

A diagnosis of Graves’ disease is made based upon a detailed patient and family history, a thorough clinical evaluation, identification of characteristic findings, and specialized tests such as blood tests that measure the levels of thyroid hormone and thyroid-stimulating hormone. Blood tests to detect the presence of specific antibodies that cause Graves’ disease can be performed to confirm a diagnosis but are usually not necessary.

Computed tomography or Magnetic Resonance Imaging (MRI) of orbits can be performed to diagnose Graves’ orbitopathy in patients who present with orbitopathy without hyperthyroidism. Patients with hyperthyroidism can have microcytic anemia, thrombocytopenia, bilirubinemia, high transaminases, hypercalcemia, high alkaline phosphatase, Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL) cholesterol.

Graves’ Disease Differential Diagnosis

The conditions that closely mimic the symptoms of Graves’ disease are listed below.

• Exogenous thyroid hormone
• Hashimoto thyroiditis
• Hyperemesis gravidarum
• Papillary thyroid carcinoma
• Pheochromocytoma
• Pituitary resistance to thyroid hormone
• Postpartum thyroiditis
• Radiation-induced thyroiditis
• Silent thyroiditis
• Struma ovarii
• Subacute thyroiditis
• Thyrotropin-producing pituitary adenomas
• Toxic multinodular goiter

Further details related to diagnosis will be provided in the report…

Graves’ Disease Epidemiology

The Graves’ disease epidemiology chapter in the report provides historical as well as forecasted epidemiology, included in prevalent and diagnosed population, segmented by total prevalent cases of Graves’ disease, total diagnosed prevalent cases of Graves’ disease, gender-specific cases of Graves’ disease, and Graves’ disease cases by manifestations in the 7MM covering the US, EU4 (Germany, France, Italy, Spain) and the UK, and Japan from 2021 to 2034.

• Among the 7MM, the US accounted for approximately 48%, EU4 and the UK for 46%, and Japan for 6% of the total prevalent cases of Graves’ disease in 2024.
• As per the DelveInsight estimates, it has been found that there were approximately  3,787,900 diagnosed prevalent cases of Graves’ disease in the 7MM in 2024.
• In 2024, the manifestation-specific cases of Graves' disease in EU4 and the UK showed that Graves' Ophthalmopathy captured the highest number of cases, i.e., approximately 682,300 cases.
• In 2024, the gender-specific diagnosed prevalent cases of Graves’ disease in Japan were approximately 80,600 cases for males and approximately 322,300 cases for females. 

Graves’ Disease Report Insights

• Patient population
• Country-wise epidemiology distribution

Graves’ Disease report key strengths

• Ten years forecast
• 7MM coverage 
• Graves’ disease epidemiology segmentation

FAQs

• What are the disease risks, burdens, and unmet needs of Graves’ disease? What will be the growth opportunities across the 7MM concerning the patient population with Graves’ disease?
• What is the historical and forecasted Graves’ disease patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.